BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/11/2022 12:39:21 AM | Browse: 374 | Download: 926
 |
Received |
|
2021-08-11 14:27 |
 |
Peer-Review Started |
|
2021-08-11 14:30 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2021-09-02 01:09 |
 |
Revised |
|
2021-09-23 15:29 |
 |
Second Decision |
|
2022-02-08 06:02 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2022-02-10 10:38 |
 |
Articles in Press |
|
2022-02-10 10:38 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2022-01-20 10:49 |
 |
Typeset the Manuscript |
|
2022-02-19 17:51 |
 |
Publish the Manuscript Online |
|
2022-03-11 00:39 |
ISSN |
2307-8960 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Pharmacology & Pharmacy |
Manuscript Type |
Case Report |
Article Title |
Escitalopram-induced hepatitis: A case report
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Guillaume Wabont, Laurie Ferret, Nicolas Houdre, Antoine Lepied, Johana Bene and Etienne Cousein |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Guillaume Wabont, PharmD, Pharmacist, Statistician, Department of Pharmacy, Valenciennes Hospital, Avenue Desandrouin, Valenciennes 59300, France. wabont.guillaume@gmail.com |
Key Words |
Escitalopram; Hepatitis; Cholestasis; Pharmacovigilance; Case report |
Core Tip |
The antidepressant escitalopram is widely prescribed for the treatment of depression. The article consists of a unique clinical case, a review of the literature and a pharmacovigilance analysis. This is the first clinical case of escitalopram as the only possible drug causing hepatitis and cholestasis. This is also the first pharmacovigilance analysis conducted to qualify and quantify the risk of hepatitis and cholestasis when using escitalopram. |
Publish Date |
2022-03-11 00:39 |
Citation |
Wabont G, Ferret L, Houdre N, Lepied A, Bene J, Cousein E. Escitalopram-induced hepatitis: A case report. World J Clin Cases 2022; 10(8): 2468-2473 |
URL |
https://www.wjgnet.com/2307-8960/full/v10/i8/2468.htm |
DOI |
https://dx.doi.org/10.12998/wjcc.v10.i8.2468 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345